<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:department>Division of Clinical Studies</gtr:department><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/440FA907-0B30-4DCB-837B-CDAAF0995552"><gtr:id>440FA907-0B30-4DCB-837B-CDAAF0995552</gtr:id><gtr:firstName>Elizabeth</gtr:firstName><gtr:surname>Cullis</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100386"><gtr:id>A24A5B74-FF97-4E9E-AA2F-B715A2EA02A9</gtr:id><gtr:title>Therapeutic Targeting of ALK in Neuroblastoma</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1100386</gtr:grantReference><gtr:abstractText>Neuroblastoma (NB) is the second most common childhood cancer. It develops from the sympathetic nervous system and the majority of children with high-risk disease die from cancer relapse despite intensive treatment. 

Changes in two cancer-causing genes, MYCN and ALK, are closely associated with poor outcome. The role of MYCN in causing high-risk NB is well recognised, but ALK was only recently identified. It is unknown whether ALK can cause NB alone, or requires an interaction with MYCN. Clinical evidence suggests that patients with concurrent abnormalities in both ALK and MYCN genes have uniquely aggressive disease and very poor survival.

Our laboratory has developed the first genetically engineered model of NB in which both MYCN and ALK are abnormal. As in patients, tumours are aggressive and survival is poor.

I hypothesise that ALK cooperates with MYCN to cause NB and will use our model to establish how MYCN and ALK cooperate and to evaluate whether drugs that attack ALK, Mycn or both proteins are needed to stop tumour growth. 

If my work succeeds, we will identify new, molecularly-targeted drugs that could be utilised in clinical trials for patients with relapsing NB. Currently these patients have no options for treatment.</gtr:abstractText><gtr:technicalSummary>Neuroblastoma (NB) is the most common non-CNS paediatric cancer. Fifty-percent of children with high-risk disease succumb to relapse. Alteration in MYCN and ALK genes correlates with aggressive tumour biology, increased tumour vascularisation and relapse. Concurrent ALK point mutations and MYCN gene amplification occur in patients with therapy-resistant tumours and poor clinical survival (15% at 5 years), implying a functional interaction between these two genes that induces an aggressive tumour phenotype.
We characterised the first MYCN-driven transgenic model of NB and used it to show that PI3-kinase pathway inhibitors destabilise Mycn protein by altering n-terminal phosphorylation. We have now developed the first ALK-driven NB transgenic model in which tumours arise exclusively in mice doubly-transgenic for MYCN and ALK. Compared to MYCN-driven tumours, MYCN/ALK-driven tumours have increased Mycn protein, reduced neovascularisation and an aggressive phenotype mirroring that of human MYCN/ALK tumours. Since ALK is known to stimulate PI3K-patwhay activity, we hypothesise that ALK potentiates MYCN-driven oncogenesis, in part, through PI3K-driven Mycn protein stabilisation. 
 
The three aims of this project are to examine: 1) whether ALK potentiates MYCN-driven NB, by stabilising Mycn protein, 2) whether ALK inhibits MYCN-driven tumour neovascularisation, and 3) whether ALK- and/or Mycn-targeted therapeutics are effective against these tumours. 

Established human and murine NB cell lines with varying expression of MYCN and phospho-mutated (stabilised) Mycn proteins will be transfected with ALK mutants to assess whether stabilisation of Mycn protein occurs through PI3K-pathway induction and Mycn phosphorylation. I will examine in parallel whether MYCN-driven angiogenesis is inhibited using in vitro angiogenesis assays with which I have extensive prior experience. In vivo tissue from MYCN and MYCN/ALK transgenic tumours will be examined for stabilisation of Mycn through assessment of PI3K pathway expression and ratio of Mycn to pMycn protein. Vessels will be analysed by pathology and expression of major angiogenic signalling proteins will be characterised. MRI will be used to quantitate tumour blood flow and size, response in preclinical studies of Mycn and ALK-targeted therapeutics (BEZ235 and PF2341066). Specifically the ability of PF-2341066 alone or in combination with BEZ235 to regress tumours and destabilise Mycn will be assessed.

This project presents a unique combination of reagents and validated approaches that will allow mechanistic dissection of the interaction between MYCN and ALK in NB, and will guide the development of targeted-therapeutics for ultra high-risk NB patients.</gtr:technicalSummary><gtr:fund><gtr:end>2015-08-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>213100</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1440</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Undergraduate Research Bursary</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>Society of Biology</gtr:fundingOrg><gtr:id>9342352A-E808-4249-AFDA-01DDA2B709D4</gtr:id><gtr:outcomeId>oNXZTh7PdgT</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>49358B87-D22D-4EA4-A388-08B5851147BF</gtr:id><gtr:title>Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56eca3e27fe3529aca6e7b05b0f7b11f"><gtr:id>56eca3e27fe3529aca6e7b05b0f7b11f</gtr:id><gtr:otherNames>Tucker ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn><gtr:outcomeId>5a9eab494672c3.09074563</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCAC39DD-A43D-4335-A3C2-824DF3C6CCD4</gtr:id><gtr:title>The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e17569fc613a2a427daad891df71bb48"><gtr:id>e17569fc613a2a427daad891df71bb48</gtr:id><gtr:otherNames>Guan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn><gtr:outcomeId>589999f5029e05.45917662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>231473DA-6580-48C9-9C7F-F78BBFA28529</gtr:id><gtr:title>Targeting ALK and MYCN in Neuroblastoma - A Paradigm for Paediatric Drug Development</gtr:title><gtr:parentPublicationTitle>Oncology News</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f40b5eb0701582f1220ac20ab616414"><gtr:id>3f40b5eb0701582f1220ac20ab616414</gtr:id><gtr:otherNames>Tucker Elizabeth</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>1751-4975</gtr:isbn><gtr:outcomeId>D2wacEEK3gL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A01B8527-4094-4F24-8D1D-2A892DB1A1CF</gtr:id><gtr:title>Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56eca3e27fe3529aca6e7b05b0f7b11f"><gtr:id>56eca3e27fe3529aca6e7b05b0f7b11f</gtr:id><gtr:otherNames>Tucker ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>56cee018126fc2.73716449</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51965DFC-5DB6-4AE6-97CA-7C53C496F807</gtr:id><gtr:title>Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma.</gtr:title><gtr:parentPublicationTitle>Radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d18d86167a18513bde160839c292ff54"><gtr:id>d18d86167a18513bde160839c292ff54</gtr:id><gtr:otherNames>Jamin Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0033-8419</gtr:issn><gtr:outcomeId>pm_14702_22_23169794</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100386</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>